These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32089398)

  • 1. Can we prevent or treat graft-versus-host disease with cellular-therapy?
    Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
    Blood Rev; 2020 Sep; 43():100669. PubMed ID: 32089398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant.
    Garcia-Rosa M; Abraham A; Bertaina A; Bhoopalan SV; Bonfim C; Cohen S; DeZern A; Louis C; Oved J; Pavel-Dinu M; Purtill D; Ruggeri A; Russell A; Sharma A; Wynn R; Boelens JJ; Prockop S
    Cytotherapy; 2023 Jun; 25(6):578-589. PubMed ID: 36941149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune regulatory cell infusion for graft-versus-host disease prevention and therapy.
    Blazar BR; MacDonald KPA; Hill GR
    Blood; 2018 Jun; 131(24):2651-2660. PubMed ID: 29728401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Umbilical cord blood-derived mesenchymal stromal cells promote myeloid-derived suppressor cell proliferation by secreting HLA-G to reduce acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Yang S; Wei Y; Sun R; Lu W; Lv H; Xiao X; Cao Y; Jin X; Zhao M
    Cytotherapy; 2020 Dec; 22(12):718-733. PubMed ID: 32811747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
    Li M; Sun K; Welniak LA; Murphy WJ
    Expert Opin Pharmacother; 2008 Sep; 9(13):2305-16. PubMed ID: 18710355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
    Gu G; Yang JZ; Zhang JQ; Sun LX
    Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence.
    Rizk M; Monaghan M; Shorr R; Kekre N; Bredeson CN; Allan DS
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1416-1423. PubMed ID: 27130504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
    Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
    Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human LAP
    Wang H; Song H; Pham AV; Cooper LJ; Schulze JJ; Olek S; Tran DQ
    Theranostics; 2019; 9(8):2315-2324. PubMed ID: 31149046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells.
    Du J; Paz K; Thangavelu G; Schneidawind D; Baker J; Flynn R; Duramad O; Feser C; Panoskaltsis-Mortari A; Negrin RS; Blazar BR
    Blood; 2017 Jun; 129(23):3121-3125. PubMed ID: 28416503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study.
    Jurado M; De La Mata C; Ruiz-García A; López-Fernández E; Espinosa O; Remigia MJ; Moratalla L; Goterris R; García-Martín P; Ruiz-Cabello F; Garzón S; Pascual MJ; Espigado I; Solano C
    Cytotherapy; 2017 Aug; 19(8):927-936. PubMed ID: 28662983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination cell therapy using mesenchymal stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation of TH1/TH2 and th17/treg cells in a murine acute graft-versus-host disease model.
    Lim JY; Park MJ; Im KI; Kim N; Jeon EJ; Kim EJ; Cho ML; Cho SG
    Cell Transplant; 2014 Apr; 23(6):703-14. PubMed ID: 23452894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.
    Hess NJ; Kink JA; Hematti P
    Front Immunol; 2023; 14():1143381. PubMed ID: 37063900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4
    Mancusi A; Piccinelli S; Velardi A; Pierini A
    Front Immunol; 2019; 10():2901. PubMed ID: 31921162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid-derived suppressor cells therapy enhance immunoregulatory properties in acute graft versus host disease with combination of regulatory T cells.
    Park MJ; Baek JA; Kim SY; Jung KA; Choi JW; Park SH; Kwok SK; Cho ML
    J Transl Med; 2020 Dec; 18(1):483. PubMed ID: 33317573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early myeloid-derived suppressor cells (HLA-DR
    Wang K; Lv M; Chang YJ; Zhao XY; Zhao XS; Zhang YY; Sun YQ; Wang ZD; Suo P; Zhou Y; Liu D; Zhai SZ; Hong Y; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    J Hematol Oncol; 2019 Mar; 12(1):31. PubMed ID: 30885244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of induced and natural FoxP3(+) regulatory T cells for the treatment of Graft-versus-host disease.
    Prinz I; Koenecke C
    Arch Immunol Ther Exp (Warsz); 2012 Jun; 60(3):183-90. PubMed ID: 22476537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
    Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
    Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.